While targeting TGF-β by ligand sequestration or by TβRI kinase inhibition attenuates pancreatic tumor growth and metastasis in mouse models [13]–[15], our findings indicate that, in certain instances, targeting both EGFR and TGF-β-dependent pathways can exert synergistic inhibitory effects on PDAC proliferation and angiogenesis. This evidence concerns the gene TGFB1 and pancreatic neoplasm.